ALKERMES | ALKS - Market Capitalization


ALKERMES reported $5.53B in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 364.22B 20.46B May/2026
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
ALKERMES USD 5.53B 909M May/2026
Amgen USD 189.89B 13.64B Mar/2026
Biogen USD 26.9B 1.09B Mar/2026
BioMarin Pharmaceutical USD 10.57B 290M May/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Coherus Biosciences USD 172M 19M Dec/2025
Eli Lilly USD 869.02B 146.97B Mar/2026
Gilead Sciences USD 152.28B 14.55B Dec/2025
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
J&J USD 579.15B 78.91B Mar/2026
Malin Corporation EUR 142.92M 19.65M Feb/2026
Merck USD 297.1B 35.84B Mar/2026
Nektar Therapeutics USD 15.62B 14.76B May/2026
Neurocrine Biosciences USD 13.34B 800M May/2026
Otsuka Holdings JPY 5.98T 1.16T Mar/2026
Ovoca Bio EUR 6.12M 4.93M Apr/2026
Pfizer USD 148.08B 6.51B May/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Vertex Pharmaceuticals USD 111.03B 2.55B May/2026